DLQ01: A Better "Minoxidil" PGF2a synthetic analogue. 2/17/2025
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity OND-1 "Cyclosporine A” New hair loss treatment
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
community Upcoming and current hair growth stimulants (2026)
The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.
community How far are we from a treatment better than finasteride?
Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.
community There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
community New Treatments (1st Gen and 2nd Gen)
Upcoming hair loss treatments are in various trial phases, with some expected by 2034-36. Current reliance remains on finasteride and minoxidil, with hopes for future non-hormonal solutions.
Related Research
6 / 6 results
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Semifluorinated Alkanes as New Drug Carriers—An Overview of Potential Medical and Clinical Applications
This review covers the current and potential medical uses of semifluorinated alkanes, including applications in eye surgery, drug delivery, and oxygen transport.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome
This study reported that alopecia occurred in 2.5% of patients with mycosis fungoides or Sézary syndrome, with some cases resembling alopecia areata and others associated with specific skin lesions.
research How effective is cryotherapy applied to the nail fold in ingrown toenails?
Cryotherapy is effective for ingrown toenails, especially in single cases, but has high recurrence in younger and bilateral cases.
research Adolescent Male Androgenetic Alopecia with Iron Deficiency Anemia: A Case Treated with Individualized Homeopathy
This case study observed that individualized homeopathic treatment, particularly Lycopodium clavatum, appeared useful in managing androgenetic alopecia comorbid with iron deficiency anemia and COVID-19 in a 17-year-old male, though the authors emphasize the need for larger studies to confirm these findings.